Nachrichten zur ImmunityBio Aktie

ImmunityBio: Anktiva Explained and What Comes Next

IBRXs Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.…

IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, May 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

ImmunityBio stock surges as FDA accepts bladder cancer filing

ImmunityBio stock surges as FDA accepts bladder cancer filing…

ImmunityBio stock gains on five new U.S. patent awards

ImmunityBio stock gains on five new U.S. patent awards…

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for ImmunityBio, Inc. (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff…

ImmunityBio acquiring U.S. rights to Tokyo strain of BCG

…

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

ImmunityBio Shareholders Between January 19, 2026 and March 24, 2026 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit…

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, May 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline

Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Did you buy IBRX securities between January 19, 2026,…

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, April 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, April 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK and NEW ORLEANS, April 14, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and…

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?…

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for ImmunityBio, Inc. (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff…

IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results

ImmunityBio stock jumps 7% as Q1 2026 revenues surge 168% on strong Anktiva uptake, with expanding approvals and pipeline progress…

IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - Contact Kirby McInerney LLP by May 26, 2026

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased ImmunityBio, Inc. (“ImmunityBio”…

ImmunityBio stock surges on $100M financing deal

ImmunityBio stock surges on $100M financing deal…

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for ImmunityBio, Inc. (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff…

ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?

IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race…

ImmunityBio shares plunge after FDA warning over misleading ads

ImmunityBio shares plunge after FDA warning over misleading ads…

ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?

IBRX stock surges nearly 300% YTD as Anktiva sales jump and global approvals expand, while premium valuation and single-drug reliance…

IBRX Stock: Anktivas Approvals and What Comes Next

ImmunityBios Anktiva drives revenue surge and new approvals, as U.S. uptake and global launches set up a pivotal 2026.…

Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%

On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion.…

ImmunityBio setzt auf das Immunsystem – EU-Zulassung treibt Biotech-Aktie an

EU-Zulassung als Gamechanger: Anktiva bekommt grünes Licht in Europa – die ImmunityBio-Aktie explodiert (zeitweise +40 %) und steht nach der…

Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal…

ImmunityBio stock rises after productive regulatory talks with Saudi FDA By Investing.com

ImmunityBio stock rises after productive regulatory talks with Saudi FDA…

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.…

Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That”

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the stocks Jim Cramer talked about, along with market froth. When a caller asked…

Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses

On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the companys heavily-shorted stock.…

ImmunityBio Inc.: Immuntherapien der nächsten Generation - D. Boral Capital sieht 259 % Kurspotenzial

Revolutionäre Immunmodulation als Kernkompetenz ImmunityBio Inc. (IBRX) hat sich von einem klassischen Biotech-Forschungsunternehmen zu einem kommerziellen Akteur im Bereich der…

ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

…

Why ImmunityBio Stock Is Skyrocketing Again Today

It has been an incredible week of positive news for ImmunityBio.…

Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more

These are the stocks posting the largest moves in premarket trading.…

ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphoma

Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses…

ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This…

ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ImmunityBio (IBRX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

ImmunityBio Inc. (IBRX): H.C. Wainwright sieht Potenzial für ANKTIVA bei therapieresistenten nicht-muskelinvasiven Blasenkrebserkrankungen

ImmunityBio Inc. (IBRX) (i.) ist ein Biotechnologieunternehmen, das sich auf die Entwicklung von Next-Generation-Therapien und Impfstoffen konzentriert, die das natürliche…

ImmunityBio shares surge following progress in FDA discussions By Investing.com

ImmunityBio shares surge following progress in FDA discussions…

ImmunityBios Cash Burn And Dilution Dampen Anktivas Potential

…

Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move

Biotech billionaire Patrick Soon-Shiong was accused in a shareholder lawsuit of misleading ImmunityBio Inc. investors about the prospects of the…

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

dpa-AFX ProFeed